MorphoSys Patents Ruled Invalid Against Janssen and Genmab

MorphoSys Patents Ruled Invalid Against Janssen and Genmab

Germany-based MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announces that it was informed today that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware, based on a hearing held...

Pin It on Pinterest